11β-Hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome

Molecular and Cellular Endocrinology

Volumn 215, Issue 1-2, 2004, Pages 45-54

  Wake, Deborah J ^a   Walker, Brian R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

11 Hydroxysteroid dehydrogenase; Adipose; Glucocorticoids; Metabolic syndrome; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; GLUCOCORTICOID; HYDROCORTISONE; ISOENZYME; MESSENGER RNA;

CONFERENCE PAPER; CUSHING SYNDROME; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSGENIC MOUSE; WHITE ADIPOSE TISSUE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; ENZYME INHIBITORS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICE; OBESITY;

EID: 1542722295     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.11.015     Document Type: Conference Paper

References (84)

1. Agarwal A.K., Monder C., Eckstein B., White P.C. Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J. Biol. Chem. 264:1989;18939-18943.
2. Alberts, P., Nilsson, C., Selen, G., Engblom, L.O., Edling, N.H., Norling, S., Klingstrom, G., Larsson, C., Forsgren, M., Ashkzari, M., Nilsson, C.E., Fiedler, M., Bergqvist, E., Eva Bjorkstrand B., Abrahmsen, L.B., 2003. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144, 4755-4762.
3. Albiston A.L., Obeyesekere V.R., Smith R.E., Krozowski Z.S. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 105:1994;R11-R17.
4. Amelung D., Huebner H.J., Roka L., Meyerheim G. Conversion of cortisone to compound F. J. Clin. Endocrinol. Metab. 12:1953;1125.
5. Andrew R., Phillips D.I.W., Walker B.R. Obesity and gender influence cortisol secretion and metabolism in man. J. Clin. Endocrinol. Metab. 83:1998;1806-1809.
6. Andrew R., Smith K., Jones G.C., Walker B.R. Distinguishing the activities of 11β-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. J. Clin. Endocrinol. Metab. 87:2002;277-285.
7. Andrews R.C., Herlihy O., Livingstone D.E.W., Andrew R., Walker B.R. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J. Clin. Endocrinol. Metab. 87:2002;5587-5593.
8. Andrews R.C., Rooyackers O., Walker B.R. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 88:2003;285-291.
9. Barf T., Vallgarda J., Emond R., Haggstrom C., Kurz G., Nygren A., Larwood V., Mosialou E., Axelsson K., Olsson R., Engblom L., Edling N., Ronquist-Nii Y., Ohman B., Alberts P., Abrahmsen L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 45:2002;3813-3815.
10. Berger J., Tanen M., Elbrecht A., Hermanowski-Vosatka A., Moller D.E., Wright S.D., Thieringer R. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J. Biol. Chem. 276:2001;12629-12635.
11. Bjorntorp P., Holm G., Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabet. Med. 16:1999;373-383.
12. Bujalska I.J., Kumar S., Hewison M., Stewart P.M. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology. 140:1999;3188-3196.
13. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect 'Cushing's disease of the omentum'? Lancet. 349:1997;1210-1213.
14. Bujalska I.J., Walker E.A., Hewison M., Stewart P.M. A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J. Clin. Endocrinol. Metab. 87:2002;1205-1210.
15. Dave-Sharma, S., Wilson, R.C., Harbison, M.D., Newfield, R, Azar, M.R., Krozowski, Z.S., Funder, J.W., Shackleton, C.L., Bradlow, H.L., Wei, J.-Q., Hertecant, J., Moran, A., Neiberger, R.E., Balfe, J.W., Fattah, A., Daneman, D., Akkurt, H.I., De Santis, C., New, M.I., 1998. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 83, 2244-2254.
16. Del Rincon, J.P., Kim, D-S., Ito, E., Hellmann, P., Thorner, M.O., 2003. 11b-Hydroxysteroid dehydrogenase type 1 transcription is not regulated by GH in visceral fat in contrast to liver and skeletal muscle. In: Proceedings of Endo, OR50-3. Ref type: abstract.
17. Di Blasio A.M., Van Rossum E.F.C., Maestrini S., Berselli M.E., Tagliaferri M., Podesta F., Koper J.W., Liuzzi A., Lamberts S.W.J. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin. Endocrinol. (Oxford). 59:2003;68-74.
18. Diedrich S., Grossmann B., Hanke B., Quinkler M., Herrmann M., Bahr V., Oelkers W. In the search for specific inhibitors of human 11b-hydroxysteroid- dehydrogenases (11βHSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-1. Eur. J. Endocrinol. 142:2000;200-207.
19. Draper N., Echwald S.M., Lavery G., Walker E.A., Fraser R., Davies E., Sorensen T.I.A., Astrup A., Adamski J., Hewison M., Connell J.M., Pedersen O., Stewart P.M. Association studies between microsatellite markers within the gene encoding for 11β-hydroxysteroid dehyrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J. Clin. Endocrinol. Metab. 87:2002;4984-4990.
20. Draper N., Walker E.A., Bujalska I., Tomlinson J.W., Chalder S.M., Arlt W., Lavery G., Bedendo O., Ray D.W., Laing I., Malunowicz E., White P.C., Hewison M., Mason P.J., Connell J.M., Shackelton C.H.L., Stewart P.M. Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nature Genet. 34:2003;434-439.
21. Edwards C.R.W., Stewart P.M., Burt D., Brett L., McIntyre M.A., Sutanto W.S., DeKloet E.R., Monder C. Localisation of 11β-hydroxysteroid dehydrogenase - tissue-specific protector of the mineralocorticoid receptor. Lancet. ii:1988;986-989.
22. Fraser R., Ingram M.C., Anderson N.H., Morrison C., Davies E., Connell J.M.C. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension. 33:1999;1364-1368.
23. Funder J.W., Pearce P.T., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 242:1988;583-585.
24. Harris H.J., Kotelevtsev Y.V., Mullins J.J., Seckl J.R., Holmes M.C. 11β-hydroxysteroid dehydrogenase type 1 null mice have altered hypothalamic-pituitary-adrenal axis activity: a novel control of glucocorticoid feedback. Endocrinology. 142:2001;114-120.
25. Hermanowski-Vosatka A., Gerhold D., Mundt S.S., Loving V.A., Lu M., Chen Y., Elbrecht A., Wu M., Doebber T., Kelly L., Milot D., Guo Q., Wang P.R., Ippolito M., Chao Y.S., Wright S.D. PPARa agonists reduce 11β- hydroxysteroid dehydrogenase type 1 in the liver. Biochem. Biophys. Res. Commun. 279:2000;330-336.
26. Hult M., Jornvall H., Oppermann U.C.T. Selective inhibition of human type 1 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett. 441:1998;25-28.
27. Jamieson P., Chapman K.E., Edwards C.R., Seckl J.R. 11β- hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of hepatocytes: effects of physiochemical and hormonal manipulations. Endocrinology. 136:1995;4754-4761.
28. Jamieson A., Wallace A.M., Walker B.R., Andrew R., Fraser R., White P.C., Connell J.M.C. Apparent cortisone reductase deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase type 1. J. Clin. Endocrinol. Metab. 84:1999;3570-3574.
29. Jessop D.S., Dallman M.F., Fleming D., Lightman S.L. Resistance to glucocorticoid feedback in obesity. J. Clin. Endocrinol. Metab. 86:2001;4109-4114.
30. Katz J.R., Mohamed-Ali V., Wood P.J., Yudkin J.S., Coppack S.W. An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin. Endocrinol. (Oxford). 50:1999;63-68.
31. Kotelevtsev Y.V., Holmes M.C., Burchell A., Houston P.M., Scholl D., Jamieson P.M., Best R., Brown R.W., Edwards C.R.W., Seckl J.R., Mullins J.J. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycaemia on obesity and stress. Proc. Natl. Acad. Sci. U.S.A. 94:1997;14924-14929.
32. Lindsay R.S., Wake D.J., Nair S., Bunt J., Livingstone D.E., Permana P.A., Tataranni P.A., Walker B.R. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and mRNA levels are associated with adiposity and insulinaemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88:2003;2738-2744.
33. Liu Y., Nakagawa Y., Wang Y., Li R., Li X., Ohzeki T., Friedman T.C. Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes. 52:2003;1409-1416.
34. Livingstone D.E., Jones G.C., Smith K., Jamieson P.M., Andrew R., Kenyon C.J., Walker B.R. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology. 141:2000;560-563.
35. Livingstone D.E.W., Walker B.R. Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J. Pharmacol. Exp. Ther. 305:2003;167-172.
36. Ljung T., Andersson B., Bengtsson B., Bjorntorp P., Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes. Res. 4:1996;277-282.
37. Ljung T., Ottosson M., Ahlberg A.C., Eden S., Oden B., Okret S., Bronnegard M., Stierna P., Bjorntorp P. Central and peripheral glucocorticoid receptor function in abdominal obesity. J. Endocrinol. Invest. 25:2002;229-235.
38. Lottenberg S.A., Giannella-Neto D., Derendorf H., Rocha M., Bosco A., Carvalho S.V., Moretti A.E., Lerario A.C., Wajchenberg B.L. Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int. J. Clin. Pharmacol. Ther. 36:1998;501-505.
39. Low S.C., Chapman K.E., Edwards C.R.W., Seckl J.R. 'Liver-type' 11β-hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS-7 cells. J. Mol. Endocrinol. 13:1994;167-174.
40. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science. 294:2001;2166-2170.
41. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., Shinyama H., Sharp M.G.F., Fleming S., Mullins J.J., Seckl J.R., Flier J.S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112:2003;83-90.
42. Monder C., Stewart P.M., Lakshmi V., Valentino R., Burt D., Edwards C.R. Licorice inhibits corticosteroid 11β-hydroxysteroid dehydrogenase of rat kidney and liver in vivo and in vitro studies. Endocrinology. 125:1989;1046-1053.
43. Moore J.S., Monson J.P., Kaltsas G., Putignano P., Wood P.J., Sheppard M.C., Besser G.M., Taylor N.F., Stewart P.M. Modulation of 11β- hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 84:1999;4172-4177.
44. Morton N.M., Holmes M.C., Fievet C., Staels B., Tailleux A., Mullins J.J., Seckl J.R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276:2001;41293-41300.
45. Morton, N. M., Paterson, J. M., Holmes, M. C., Walker, B. R., Mullins, J. J., Seckl, J. R., 2002. 11β-Hydroxysteroid dehydrogenase type 1 null mice resist dietary obesity and its metabolic complications. In: Proceedings of Endo, OR17-3. Ref type: abstract.
46. Morton, N.M., Paterson, J.M., Masuzaki H., Holmes, M.C., Staels, B., Fievert, C., Walker, B.R., Flier, J.S., Mullins, J.J., 2003. Reduced 11β-Hydroxysteroid dehydrogenase type-1-mediated intra-adipose glucocorticoid regeneration: a novel protective adaptation to and treatment for the metabolic syndrome. In: Proceeding of Endo, OR39-5. Ref type: abstract.
47. Mune T., Rogerson F.M., Nikkila H., Agarwal A.K., White P.C. Human hypertension cause by mutations in the kidney isozyme of 11β- hydroxysteroid dehydrogenase type. Nature Genet. 10:1995;394-399.
48. Napolitano A., Voice M.W., Edwards C.R.W., Seckl J., Chapman K.E. 11b-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependant and hormonally regulated. J. Steroid Biochem. Mol. Biol. 64:1998;251-260.
49. Pasquali R. Is the hypothalamic-pituitary-adrenal axis really hyperactivated in human obesity? J. Endocrinol. Invest. 21:2003;268-271.
50. Paulmyer-Lacroix O., Boullu S., Oliver C., Alessi M.C., Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J. Clin. Endocrinol. Metab. 87:2002;2701-2705.
51. Phillipou G., Palermo M., Shackleton C.H.L. Apparent cortisone reductase deficiency a unique form of hypercortisolism. J. Clin. Endocrinol. Metab. 81:1996;3855-3860.
52. Rask E., Olsson T., Soderberg S., Andrew R., Livingstone D.E.W., Johnson O., Walker B.R. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 86:2001;1418-1421.
53. Rask E., Walker B.R., Soderberg S., Livingstone D.E.W., Eliasson M., Johnson O., Andrew R., Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 87:2002;3330-3336.
54. Reynolds R.M., Walker B.R., Phillips D.I.W., Sydall H.E., Andrew R., Wood P.J., Whorwood C.B. Altered control of cortisol secretion in adult men with low birthweight and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 86:2001;245-250.
55. Rodin A., Thakkar H., Taylor N., Clayton R. Hyperandrogenism in polycystic ovary syndrome: evidence of dysregulation of 11β-hydroxysteroid dehydrogenase. N. Eng. J. Med. 330:1994;460-465.
56. Rosmond R., Chagnon Y.C., Chagnon M., Perusse L., Bouchard C., Bjorntorp P. A polymorphism of the 5′-flanking region of the glucocorticoid receptor gene locus is associated with basal cortisol secretion in men. Metabolism. 49:2000;1197-1199.
57. Rosmond R., Dallman M.F., Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and haemodynamic abnormalities. J. Clin. Endocrinol. Metab. 83:1998;1853-1859.
58. Seckl J.R., Walker B.R. 11b-Hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology. 142:2001;1371-1376.
59. Stewart P.M., Boulton A., Kumar S., Clark P.M.S., Shackleton C.H.L. Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J. Clin. Endocrinol. Metab. 84:1999;1022-1027.
60. Stewart P.M., Krozowski Z.S. 11β-hydroxysteroid dehydrogenase. Vitam. Horm. 57:1999;249-324.
61. Stewart P.M., Shackleton C.H.L., Beastall G.H., Edwards C.R.W. 5alpha-reductase activity in polycystic ovarian syndrome. Lancet. 335:1990;431-433.
62. Stewart P.M., Sheppard M.C. Novel aspects of hormone action: intracellular ligand supply and its control by a series of tissue-specific enzymes. Mol. Cell. Endocrinol. 83:1992;C13-C18.
63. Stewart P.M., Valentino R., Wallace A.M., Burt D., Shackelton C.H.L., Edwards C.R.W. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 2:1987;821-824.
64. Strain G.W., Zumoff B., Kream J., Stain J.J., Levin J., Fukushima D. Sex Differences in the inluence of obesity on the 24 h mean plasma concentration of cortisol. Metabolism. 31:1982;209-212.
65. Tiosano D., Eisentein I., Militianu D., Chrousos G.P., Hochberg Z. 11β-Hydroxysteroid dehydrogenase activity in hypothalamic obesity. J. Clin. Endocrinol. Metab. 88:2003;379-384.
66. Tomlinson J.W., Crabtree N.C.P.M.S., Holder G., Toogood A.A., Shackelton C.H.L., Stewart P.M. Low-dose growth hormone inhibits 11β-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J. Clin. Endocrinol. Metab. 88:2003;2113-2118.
67. Tomlinson J.W., Moore J., Cooper M.S., Bujalska I., Shahmanesh M., Burt C., Strain A., Hewison M., Stewart P.M. Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology. 142:2001;1982-1989.
68. Tomlinson J.W., Sinha B., Bujalska I., Hewison M., Stewart P.M. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J. Clin. Endocrinol. Metab. 87:2002;5630-5635.
69. Trainer P.J., Drake W.M., Perry L.A., Taylor N.F., Besser G.M., Monson J.P. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J. Clin. Endocrinol. Metab. 86:2001;2989-2992.
70. Valentino R., Tommaselli A.P., Savastano S., Stewart P.M., Ghiggi M.R., Galletti F., Mariniello P., Lombardi G., Edwards C.R. Alcohol inhibits 11β-hydroxysteroid dehydrogenase activity in rat kidney and liver. Horm. Res. 43:2003;176-180.
71. Van Rossum E.F.C., Koper J.W., Huizenga N.A.T.M., Uitterlinden A.G., Janssen J.A.M.J., Brinkmann A.O., Grobbee D.E., de Jong F.H., Van Duyn C.M., Pols H.A.P., Lamberts S.W.J. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes. 51:2002;3128-3134.
72. Vicennati V., Ceroni L., Gagliardi L., Gambineri A., Pasquali R. Response of the hypothalamic-pituitary-adrenocortical axis to high-protein/fat and high-carbohydrate meals in women with different obesity phenotypes. J. Clin. Endocrinol. Metab. 87:2002;3984-3988.
73. Voice M.W., Seckl J.R., Chapman K.E. The sequence of 5′ flanking DNA from the mouse 11β-hydroxysteroid dehydrogenase type 1 gene and analysis of putative transcription factor binding sites. Gene. 181:1996;233-235.
74. Wake D.J., Rask E., Livingstone D.E.W., Soderberg S., Olsson T., Walker B.R. Local and systemic impact of transcriptional upregulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88:2003;2983-2988.
75. Walker B.R., Campbell J.C., Fraser R., Stewart P.M., Edwards C.R.W. Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin. Endocrinol. (Oxford). 27:1992;483-492.
76. Walker B.R., Connacher A.A., Lindsay R.M., Webb D.J., Edwards C.R. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 80:1995;3155-3159.
77. Walker B.R., Soderberg S., Lindahl B., Olsson T. Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J. Intern. Med. 247:2000;198-204.
78. Weaver J.U., Thaventhiran L., Noonan K., Burrin J.M., Taylor N.F., Norman M.R., Monson J.P. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin. Endocrinol. (Oxford). 41:1994;639-648.
79. Westerbacka, J., Yki-Jarvinen, H., Vehkavaara, S., Hakkinen, A.-M., Andrew, R., Wake, D.J., Seckl, J.R., Walker, B.R., 2003. Body fat distribution and cortisol metabolism in healthy men: enhanced 5β-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J. Clin. Endocrinol. Metab, in Press.
80. White P.C., Mune T., Agarwal A.K. 11b-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrine Rev. 18:1997;135-156.
81. Williams L.J.S., Lyons V., MacLeod I., Rajan V., Darlington G.J., Poli V., Seckl J.R., Chapman K.E. C/EBPa regulates hepatic transcription of 11β-hydroxysteroid dehydrogenase type 1 a novel mechanism for cross-talk between the C/EBP and glucocorticoid signalling pathways. J. Biol. Chem. 275:2000;30232-30239.
82. Yang K., Khalil M.W., Strutt B.J., Killinger D.W. 11b-Hydroxysteroid dehydrogenase 1 activity and gene expression in human adipose stromal cells: effect on aromatase activity. J. Steroid Biochem. Mol. Biol. 60:1997;247-253.
83. Yau J.L.W., Noble J.M., Kenyon C.J., Hibberd C., Kotelevtsev Y.V., Mullins J.J., Seckl J.R. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc. Natl. Acad. Sci. U.S.A. 98:2001;4716-4721.
84. Zhang Y.D., Wang M.S. Inhibition of 11β-hydroxysteroid dehydrogenase obtained from guinea pig kidney by some bioflavinoids and triterpenoids. Zhongguo Yao Li Xue. 18:1997;240-244.